Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Clinical Translation of Organoids and Organs-on-Chips 2022

Matthias von Herrath's Biography

Matthias von Herrath, Vice President and Senior Medical Officer, Novo Nordisk, Professor, La Jolla Institute

Dr. Matthias von Herrath is committed to clinical translation of immune-based interventions in autoimmune and metabolic diseases, the latter in particular being an exciting emerging field. His expertise and main strength is working at the interface of experimental research to interpret and refine early phase I/II clinical trials in order to optimize strategies for phase 3 trials and drug approval. This comprises translation from various animal models to human interventions, optimization of immunotherapies and their relative ranking, assessment of combination therapies, development of biomarkers as primary or secondary outcomes, induction of antigen specific tolerance in autoimmunity, regulatory cells and clinical T cell assays. In order to be better able to pursue his goal of clinical translation, Dr. von Herrath accepted the position of Vice President and Head of Novo Nordisk’s diabetes R&D Center in Seattle in autumn of 2011. At Novo Nordisk, he built the diabetes translational unit, which is based on less conventional and innovative design. In addition, he took on the task of finding new treatments to diabetic kidney disease in 2017. In 2018 he moved to the CMO office as many of the interventions are now at a later developmental stage and the position allows bridging between patient needs and trial design, biomarkers and basic mechanistic insight.

Understanding disease pathology remains very close to Dr. von Herrath’s heart and Novo Nordisk enabled him to keep an appointment at La Jolla Institute, where he pursues NIH-funded research on the pathology of type 1 and 2 diabetes as part of the national pancreatic organ donor network (nPOD). This is a multinational collaborative effort where data are shared in real time and no intellectual property yet lots of new knowledge on the pathology of type 1 and 2 diabetes is being generated. It is a unique new collaborative paradigm for academic and also industry settings.

Matthias von Herrath Image

Using Organoids to Re-Enact the Destruction of Human Beta cCells and Probe Novel Ways to Protect Them

Tuesday, 22 March 2022 at 13:30

Add to Calendar ▼2022-03-22 13:30:002022-03-22 14:30:00Europe/LondonUsing Organoids to Re-Enact the Destruction of Human Beta cCells and Probe Novel Ways to Protect ThemClinical Translation of Organoids and Organs-on-Chips 2022 in

Replacement of beta cell function through stem cell derived islets has advanced tremendously in the recent years with the prospect of providing a potential cure for many patients.  However, newly implanted islets are unfortunately still subject to allo-immunity and recurring autoimmunity. To protect the cells and to circumvent the need for full immune suppression, which can have many adverse effects, various strategies are being used to stealthen the new islets. As there are many possibilities and human trials are lengthy and complex, we built an organoid-based 3D model to re-enact the events that lead to allo- and auto-immune destruction of beta cells together with the company In Sphero. This model allows for functional and quantitative readout of beta cell function on a rather continuous basis and thus can be an eminent tool to prioritize critical steps for a clinical translational strategy and define, which changes are needed to make stem cell derived islets immune evasive.

Add to Calendar ▼2022-03-21 00:00:002022-03-22 00:00:00Europe/LondonClinical Translation of Organoids and Organs-on-Chips 2022Clinical Translation of Organoids and Organs-on-Chips 2022 in